PCI Welcomes Tadataka Yamada, Former Head of GSK and Takeda R&D, to Board of Directors
Packaging Coordinators Inc. (PCI) is pleased to welcome the addition of Dr Tadataka Yamada to its Board of Directors. Dr Yamada recently rejoined Frazier Healthcare, a principal owner of PCI, as a Venture Partner on the Life Sciences team. Prior to his role with Frazier Healthcare, Dr Yamada served as Chief Medical and Scientific Officer at Takeda Pharmaceuticals in Tokyo, as well as serving on the Takeda Board of Directors. Dr Yamada has also served as President of the Bill & Melinda Gates Foundation Global Health Program, in addition to having served as Chairman of R&D at GlaxoSmithKline, where he also served on the Board of Directors.
“We could not be more pleased to have someone of Dr Tadataka Yamada’s intelligence and experience join our Board of Directors,” states Bill Mitchell, PCI President and CEO. “He brings a level of insight and practical experience that is truly invaluable as we continue to expand the breadth of our service offering to our clients. Our ongoing strategy is to align our portfolio of services to truly meet our client needs as part of a strategic outsourcing partnership. Dr Yamada understands the pharmaceutical and biotech industry better than anyone. His presence and guidance is a tremendous asset for PCI.”
In late 2014 PCI acquired two adjacent businesses, Penn Pharma and Biotec Services International, significantly expanding its breadth of services and drug development offering. PCI now offers a comprehensive service portfolio which begins at Phase I clinical trial and extends for the entirety of the drug lifecycle, with services including drug manufacturing, clinical trials packaging and logistics, analytical laboratory services, as well as commercial manufacturing and packaging services. With a supply network located across North America and Europe, PCI supports lifesaving medicines destined to over 100 countries globally.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance